A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant)

NCT ID: NCT07349017

Last Updated: 2026-01-16

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 160 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-02-07
• Study Completion Date: 2027-03-07

Brief Summary

The goal of this clinical trial is to evaluate the safety and immunogenicity of the influenza virus vaccine (BK-01 adjuvant) in people aged 18 years and older.

The main questions it aims to answer is:

• Incidence rate of adverse reactions/events after administration Participants will be randomly vaccinated with a single dose of the trial vaccine, control vaccine, adjuvant placebo, or placebo in a 1:1:1:1 ratio. After vaccination, all participants will undergo up to 30-day observation and blood collection.

Conditions

Influenza

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

influenza vaccine（BK01 adjuvant）

Group Type: EXPERIMENTAL

influenza vaccine（BK01 adjuvnat）

Intervention Type: BIOLOGICAL

Each human dose is 0.5 mL, containing 15 μg of hemagglutinin from each type of influenza virus strain.

approved influenza vaccine

Group Type: ACTIVE_COMPARATOR

approved influenza vaccine

Intervention Type: BIOLOGICAL

Each human dose is 0.5 mL, containing 15 μg of hemagglutinin from each type of influenza virus strain.

adjuvant placebo

Group Type: PLACEBO_COMPARATOR

adjuvant placebo

Intervention Type: BIOLOGICAL

Each human dose is 0.5 mL, containing no influenza virus strain hemagglutinin. The main ingredient is BK-01 adjuvant.

placebo

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: BIOLOGICAL

Each human dose is 0.5 mL. The main ingredient is sodium chloride.

Interventions

influenza vaccine（BK01 adjuvnat）

Each human dose is 0.5 mL, containing 15 μg of hemagglutinin from each type of influenza virus strain.

Intervention Type: BIOLOGICAL

approved influenza vaccine

Each human dose is 0.5 mL, containing 15 μg of hemagglutinin from each type of influenza virus strain.

Intervention Type: BIOLOGICAL

adjuvant placebo

Each human dose is 0.5 mL, containing no influenza virus strain hemagglutinin. The main ingredient is BK-01 adjuvant.

Intervention Type: BIOLOGICAL

placebo

Each human dose is 0.5 mL. The main ingredient is sodium chloride.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Participants aged 18 years and above;
• Have not received any influenza vaccine in the past six months and have no plan to receive other influenza vaccines during the trial period;
• Have not had influenza in the past 6 months (confirmed by any clinical, serological, or microbiological method);
• Able to obtain the participant's own informed consent;
• The participant themselves can comply with the requirements of the clinical trial protocol.

Exclusion Criteria

• Axillary temperature > 37.0℃ on the day of enrollment;
• Female participants of childbearing age with a positive urine pregnancy test result, or who are breastfeeding, or have a plan to have children within 12 months;
• Those with a history of severe allergic diseases (such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrotic reaction), or who are allergic to any component of the test vaccine, such as eggs, gentamicin sulfate, formaldehyde, TritonX-100, etc.;
• Those with clinically significant abnormal laboratory test results, which are determined by the researcher as unsuitable for vaccine vaccination；
• Those who have had an acute illness, acute exacerbation of a chronic disease, or used antipyretic, analgesic, or anti-allergic drugs within the past 3 days;
• Autoimmune diseases or immune deficiency, asplenia, functional asplenia, and asplenia or splenectomy caused by any condition; those who have received long-term systemic drugs within the past 3 months or plan to receive long-term systemic drugs during the trial, including immunosuppressive and/or immunomodulatory drugs, leukotoxic therapy, etc. (for more than 14 consecutive days);
• Those with congenital malformations affecting organ function, Down's syndrome, major diseases or major potential diseases that may interfere with or hinder the completion of the trial (such as: severe cardiovascular or chronic diseases in the decompensated stage, cor pulmonale, pulmonary edema, severe liver and kidney diseases, severe or symptomatic diabetes, current malignant tumors, etc.);
• Those with uncontrolled hypertension with drugs (18-59 years old: systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg; ≥ 60 years old: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg);
• Those with a history or family history of mental and neurological diseases such as convulsions, epilepsy, encephalopathy, and psychosis; Those with contraindications to intramuscular injection and blood collection, such as: diagnosed with sickle cell anemia, thrombocytopenia, any coagulation disorder, or receiving anticoagulant therapy, etc.;
• Those who have received blood products or immunoglobulin products within 3 months before receiving the test vaccine or plan to use them during the trial;
• Those who have received other clinical trial drugs within 1 month before receiving the test vaccine or are participating in other clinical trials, received live attenuated vaccines, viral vector vaccines, or nucleic acid vaccines within 14 days, or received subunit, recombinant, or inactivated vaccines within 7 days;

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Changchun BCHT Biotechnology Co.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Chen Xin

Role: CONTACT

chenxin@bchtpharm.com

0431-87078295

Other Identifiers

B1701-F20240612-1

Identifier Type: -

Identifier Source: org_study_id